A Study of BON-C1393 in Adults With Advanced Solid Tumors
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BON-C1393 in Patients With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-C1393 monotherapy or in combination with other anticancer regimens in adults with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Dose Exploration) and Phase 1b (Dose Expansion).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Advanced solid tumors are malignant cancers that develop in organs of the body. They spread to other parts of the body and may reoccur after treatment, or no longer respond to available therapies or surgery. Many people with advanced solid tumors have limited treatment options, and their cancer may continue to grow or spread. Therefore, there is an ongoing need to develop novel therapies that may improve tumor control and prolong survival.
BON-C1393 is a targeted cancer medicine called an antibody-drug conjugate (ADC). An ADC consists of an antibody linked to a drug that can kill cancer cells. The antibody part of BON-C1393 attaches to proteins that are found on the surface of cancer cells. After it attaches to these proteins, BON-C1393 enters the cancer cell where the drug causes DNA damage and cell death.
The purpose of this study is to test whether BON-C1393 is safe and if it can help treat adults with selected advanced solid tumors.
This study consists of 2 parts, one called dose escalation and dose exploration (Phase 1a) and one called dose expansion (Phase 1b). During the dose escalation and dose exploration part, the study doctors will test different doses of the study drug to find the recommended dose that people can take without having serious side effects.
During the dose expansion part, the study doctors will test the study drug in a larger number of people using the doses identified from Phase 1a. The study will enroll adults with advanced solid tumors at multiple centers in the Asia-Pacific region.
The overall time to participate in this study is approximately 9 months for Phase 1a and approximately 12 months for Phase 1b. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Study Director
- Número de telefone: 1.877.828.5568
- E-mail: clinicaltrials@beonemed.com
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic solid tumor intolerant, refractory to or progressing after standard systemic therapies.
-
Must be able to provide archival tumor tissue (formalin-fixed, paraffin-embedded tissue block (FFPE) block or approximately 10-15 freshly cut unstained FFPE slides)
-
Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.0
-
Must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study drug(s):
a. Must not have required blood transfusion or growth factor support ≤ 14 days before sample collection at screening for the following:
-
Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.
-
Platelets ≥ 100 × 109/L.
-
Hemoglobin ≥ 90 g/L. b. Estimated glomerular filtration rate (GFR) ≥ 50 mL/min, as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) c. Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (total bilirubin must be ≤ 3 × ULN with direct bilirubin ≤ 1.5 × ULN for patients with Gilbert's syndrome).
d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN or < 5 × ULN if hepatic metastases are present.
e. Albumin ≥ 2.0 g/dL. f. In Phase 1b Part D, for patients receiving combination therapy with bevacizumab, additional inclusion criteria are listed below:
-
Urine dipstick for proteinuria < 2+ (within 7 days prior to initiation of study treatment). Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.
-
Coagulation parameters: international normalized ratio (INR) of ≤ 1.5 (or an in-range INR of ≤ 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) < 1.2 × ULN.
-
Female of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 7 months after the last dose of BON-C1393, for ≥ 6 months after the last dose of bevacizumab or capecitabine, whichever comes later. They must also have a negative urine or serum pregnancy test result ≤ 3 days before first dose of study drug/treatment.
-
Nonsterile male must be willing to use condom and refrain from sperm donation for the duration of the study and for ≥ 4 months after the last dose of BON-C1393, for ≥ 3 months after the last dose of capecitabine, whichever comes later.
Exclusion Criteria:
- Prior treatment with any B7 homolog 3 (B7-H3) or integrin beta-6 (ITGB-6) -targeted antibody-drug conjugate (ADCs) or ADCs containing topoisomerase inhibitor (TOP) inhibitor as payload.
- History of severe allergic reactions, severe reaction to infusion, or hypersensitivity to the active ingredient and excipients of the study drug(s) or protein-based therapeutics.
- Unable to comply with the requirements of the protocol, unless the written approval of the medical monitor has been obtained before informed consent.
- Active hepatitis C.
- Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
- Any major surgical procedure ≤ 28 days (or ≤ 14 days for low-invasive cases [eg, colostomy]) before the first dose of study drug. Must have recovered adequately from the surgery and/or complications from the surgical procedures before the first dose of study drug/treatment.
Any of following treatments before the first dose of study drug:
-
Prior systemic anticancer therapy (including targeted therapy and immunomodulators [eg, interleukin (IL), interferon, thymosin, etc]) ≤ 14 days, ≤ 28 days for immuno-oncological antibody, ≤14 days or 5 half-lives (whichever is shorter) for chemotherapy, ADCs, or investigational therapy.
-
Radiation therapy (curative) and palliative radiation therapy to the chest ≤ 4 weeks; ≤ 2 weeks for palliative radiation therapy to other areas (ie, limited field and 10 or fewer days or fractions) including whole-brain radiotherapy.
-
Chinese patent medicine with anticancer activity approved by the China National Medical Products Administration (NMPA) (regardless of the type of cancer) ≤ 14 days.
-
Herbal remedies with immune-stimulating properties (eg, mistletoe extract) or that are known to potentially interfere with liver or other major organ functions (eg, hypericin) ≤ 14 days or 5 half-lives, whichever is shorter or known.
- Ongoing treatment with a strong cytochrome cytochrome (CYP)3A inhibitor, or strong CYP3A inducer, or strong CYP1A2 inhibitor, or strong CYP1A2 inducer.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Phase 1a Part A: Monotherapy Dose Escalation
Sequential cohorts of increasing dose levels of BON-C1393 will be evaluated. |
Administered intravenously |
|
Experimental: Phase 1a Part B: Monotherapy Dose Exploration
Participants with select advanced solid tumors will receive BON-C1393 at 2 - 3 selected dose levels that have been determined to be safe in Part A. |
Administered intravenously |
|
Experimental: Phase 1b Part C: Monotherapy Dose Expansion
Participants with select advanced solid tumors will receive BON-C1393 as monotherapy at the recommended doses for expansion (RDFEs) identified in Phase 1a. |
Administered intravenously |
|
Experimental: Phase 1b Part D: Dose Expansion Combination Therapy
Participants with select advanced solid tumors will receive BON-C1393 in combination with bevacizumab and capecitabine. |
Administered orally Administered intravenously Administered intravenously |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)
Prazo: Approximately 1 month
|
Approximately 1 month
|
|
|
Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Prazo: Up to approximately 9 months
|
Up to approximately 9 months
|
|
|
Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator
Prazo: Up to approximately 12 months
|
ORR is defined as the percentage of participants with a best overall response (BOR) of partial response (PR) or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to approximately 12 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator
Prazo: Up to approximately 9 months
|
ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
Up to approximately 9 months
|
|
Phase 1a: Duration of Response (DOR) Assessed by the Investigator
Prazo: Up to approximately 9 months
|
DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 9 months
|
|
Phase 1b: Duration of Response (DOR) Assessed by the Investigator
Prazo: Up to approximately 12 months
|
DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 12 months
|
|
Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator
Prazo: Up to approximately 9 months
|
DCR is defined as the percentage of participants with a BOR of a CR, PR, or stable disease (SD) per RECIST v1.1. |
Up to approximately 9 months
|
|
Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator
Prazo: 12 Weeks
|
DCR at 12 weeks is defined as the percentage of participants with CR, PR, or SD per RECIST v1.1, and are alive and progression-free at Week 12. |
12 Weeks
|
|
Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator
Prazo: 24 weeks
|
DCR at 24 weeks is defined as the percentage of participants with CR, PR, or SD according to RECIST v1.1, and are alive and progression-free at the Week 24. |
24 weeks
|
|
Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator
Prazo: Up to approximately 12 months
|
PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
Up to approximately 12 months
|
|
Area Under the Concentration Time Curve (AUC) of BON-C1393
Prazo: Up to approximately 3 months
|
Up to approximately 3 months
|
|
|
Maximum Observed Plasma Concentration (Cmax) of BON-C1393
Prazo: Up to approximately 8 months
|
Up to approximately 8 months
|
|
|
Time to Maximum Plasma Concentration (Tmax) of BON-C1393
Prazo: Up to approximately 8 months
|
Up to approximately 8 months
|
|
|
Terminal Half-Life (t1/2) of BON-C1393
Prazo: Up to approximately 3 months
|
Up to approximately 3 months
|
|
|
Plasma Concentrations of BON-C1393
Prazo: Up to approximately 12 months
|
Up to approximately 12 months
|
|
|
Phase 1b: Number of Participants with Adverse Events
Prazo: Up to approximately 12 months
|
Up to approximately 12 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Diretor de estudo: Study Director, BeOne Medicines
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Nucleosídeos
- Uracil
- Pirimidinonas
- Desoxirribonucleosídeos
- Fluorouracil
- Capecitabina
- Bevacizumabe
Outros números de identificação do estudo
Outros números de identificação do estudo
- BON-C1393-101
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Prazo de Compartilhamento de IPD
See plan description
Critérios de acesso de compartilhamento IPD
See plan description
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .